NURDEN, A. T.; PILLOIS, X.

doi:10.1080/09537104.2017.1371291

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

NURDEN, A. T.

PILLOIS, X.
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases

Idioma

Article de revue

Este ítem está publicado en

Platelets. 2018-01, vol. 29(1), n° 98-101

Resumen en inglés

Studies on Glanzmann thrombasthenia (GT) helped discover the αIIbβ3 integrin and led to successful antithrombotic therapy [1,2]. GT is defined by a lack of platelet aggregation with physiological agonists, but a normal response to ristocetin. Historically, patients have been segregated into three groups: type I where platelets lack αIIbβ3 (by definition \textless5% of the normal platelet content), type II with residual αIIbβ3 (usually 5–15%) that may be functional or not, while in type III or variant GT αIIbβ3 fails to function despite platelets having up to 100% of normal levels [3]. αIIbβ3 assures platelet aggregation by changing from a bent to an extended and open form on platelet activation, conformational changes that allow fibrinogen (Fg) or other adhesive proteins to bind and crosslink platelets [4]. The absence of this function causes severe mucocutaneous bleeding and perhaps underestimated nonhemostatic defects often linked to loss of the wider biological expression of αvβ3 [5]. Inherited thrombocytopenia and increased platelet size associate with a GT-like phenotype in rare families [6]. ...< Leer menos

Palabras clave

Article RECHERCHE

Metadatos

Compartir este ítem

Licencia de uso del documento

ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave

URI

DOI

Centros de investigación